Abstract:The number of lung transplantations is limited due to the shortage of donor lungs fulfilling the standard criteria. The ex vivo lung perfusion (EVLP) technique provides the ability of re-evaluating and potentially improving and treating marginal donor lungs. Accordingly, the technique has emerged as an essential tool to increase the much-needed donor lung pool. One of the major EVLP protocols, the Lund protocol, characterized by high pulmonary artery flow (100% of cardiac output [CO]), an open atrium, and a cellular perfusate, has demonstrated encouraging short-EVLP duration results. However, the potential of the longer EVLP duration of the protocol is yet to be investigated, a duration which is considered necessary to rescue more marginal donor lungs in future. This study aimed to achieve stable 8-h EVLP using an open-atrium cellular model with three different pulmonary artery flows in addition to determining the most optimal flow in terms of best lung performance, including lung electrolytes and least lung edema formation, perfusate and tissue inflammation, and histopathological changes, using the porcine model. EVLP was performed using a flow of either 40% ( n = 6 ), 80% ( n = 6 ), or 100% ( n = 6 ) of CO. No flow rate demonstrated stable 8-h EVLP. Stable 2-h EVLP was observed in all three groups. Insignificant deterioration was observed in dynamic compliance, peak airway pressure, and oxygenation between the groups. Pulmonary vascular resistance increased significantly in the 40% group (p < .05). Electrolytes demonstrated an insignificant worsening trend with longer EVLP. Interleukin-8 (IL-8) in perfusate and tissue, wet-to-dry weight ratio, and histopathological changes after EVLP were insignificantly time dependent between the groups. This study demonstrated that stable 8-h EVLP was not feasible in an open-atrium cellular model regardless of the flow of 40%, 80%, or 100% of CO. No flow was superior in terms of lung performance, lung electrolytes changes, least lung edema formation, minimal IL-8 expression in perfusate and tissue, and histopathological changes.

Blood donor screening for parvovirus B19 in Germany and Austria

Histologic and functional evaluation of lungs reconditioned by ex vivo lung perfusion

The Conversional Efficacy of Ex Vivo Lung Perfusion and Clinical Outcomes in Patients Undergoing Transplantation of Donor Lungs by Ex Vivo Lung Perfusion: A Meta-Analysis.

A New Way Forward to Expand the Donor Pool

Perfusate adsorption during ex vivo lung perfusion improves early post-transplant lung function

Ex vivo lung perfusion with perfusate purification for human donor lungs following prolonged cold storage

A Split-Lung Ex Vivo Perfusion Model for Time- and Cost-Effective Evaluation of Therapeutic Interventions to the Human Donor Lung

Prone ex vivo lung perfusion protects human lungs from reperfusion injury

The impact of ex vivo lung perfusion location on lung transplant outcomes

Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion

Transplant Suitability of Rejected Human Donor Lungs With Prolonged Cold Ischemia Time in Low-Flow Acellular and High-Flow Cellular Ex Vivo Lung Perfusion Systems

Cost effectiveness of commercial portable ex vivo lung perfusion at a low‐volume US lung transplant center

Inhalative pre-treatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury

Transcription of carcinoembryonic antigen in normal colon and colon carcinoma. In situ hybridization study and implication for a new in vivo functional model.

Cost-effective Donor Lung Preservation with High-Volume Continuous Perfusate Purification in Ex Vivo Lung Perfusion

Porcine lungs perfused with three different flows using the 8-h open-atrium cellular ex vivo lung perfusion technique

Therapeutic reconditioning of damaged lungs by transient heat stress during ex vivo lung perfusion

Letter: Oral dihydroergotamine in management of cluster headache.

The contribution of donor management and modified cold blood lung perfusate to post-transplant lung function

The current status of stem cell‐based therapies during ex vivo graft perfusion: an integrated review of four organs

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.